Terns Pharmaceuticals
TERN
TERN was delisted on the 4th of May, 2026.
36 hedge funds and large institutions have $204M invested in Terns Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 12 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
8.56% less ownership
Funds ownership: 74.7% → 66.14% (-8.6%)
14% less funds holding
Funds holding: 42 → 36 (-6)
48% less capital invested
Capital invested by funds: $394M → $204M (-$190M)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.3M |
| 2 |
CAC
Cowen and Company
New York
|
+$1.02M |
| 3 |
BlackRock
New York
|
+$515K |
| 4 |
State Street
Boston,
Massachusetts
|
+$512K |
| 5 |
Morgan Stanley
New York
|
+$457K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$8.8M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$7.24M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$5.61M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$3.55M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.73M |
TERN Hedge Fund Activity: Q2 2021 in Review
36 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q2 2021, worth a combined $204M — down 48% from $394M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of TERN and 6 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 11 added.
The largest buyer was Fidelity Investments, adding an estimated $2.3M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $8.8M sold.
- 36 institutional investors held Terns Pharmaceuticals (TERN) as of Q2 2021, down from 42 in Q1 2021.
- Funds reported $204M of Terns Pharmaceuticals stock for Q2 2021, down 48% quarter-over-quarter.
- 6 funds opened new Terns Pharmaceuticals positions in Q2 2021 and 12 closed out, a net change of -6 holders.
- The largest Terns Pharmaceuticals buyer in Q2 2021 was Fidelity Investments, an estimated $2.3M added.
- The largest Terns Pharmaceuticals seller in Q2 2021 was Avidity Partners Management, an estimated $8.8M sold.
Based on aggregated 13F filings for Q2 2021.